NewcelX develops stem-cell-derived therapies, led by NCEL-101, insulin-producing islet cells for type 1 diabetes; none is approved.
NewcelX's case rests on NCEL-101, insulin-producing islet cells made from stem cells, given with Eledon's anti-CD40L antibody tegoprubart to prevent rejection in type 1 diabetes. FDA gave favorable feedback at a July pre-IND meeting, and NewcelX is moving to IND-enabling work; no IND date has been given. AstroRx, its ALS cell therapy, finished an early trial in Israel. NewcelX had $0.71 million of cash at June 30 and priced a $1.4 million private placement in July; it states substantial doubt about continuing.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: NCEL-101 reaches an IND
Does NewcelX complete IND-enabling work and submit the NCEL-101 IND?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
NewcelX has FDA guidance for NCEL-101 but only $710,000 of cash
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Competitive landscape
9 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.